Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following is a G protein coupled receptor?

M2 muscarinic receptor. ***M2 muscarinic receptor***- The **M2 muscarinic receptor** is a classic example of a **G protein-coupled receptor (GPCR)** [1]. When a ligand binds to a G-protein-coupled receptor, it triggers a mechanism where GDP is exchanged for GTP, causing the G-protein's alpha subunit to separate and initiate signaling pathways [1]. These heterotrimeric G-proteins couple cell surface receptors to catalytic units that form second messengers or directly to ion channels [1]. GPCRs are important regulators of nerve activity in the CNS and are receptors for neurotransmitters of the peripheral autonomic nervous system, with acetylcholine (ACh) being a ligand that regulates functions of glands and smooth muscle [2]. The **M2 muscarinic receptor** specifically activates an **inhibitory G protein (G_i)**, leading to a decrease in **cAMP** and opening of **potassium channels**. The effects of metabotropic receptors, like GPCRs, can last tens of seconds to minutes, contrasting with the brief effects of ionotropic receptors [4].*NMDA receptor*- The **NMDA receptor** is a **ligand-gated ion channel** that allows the influx of calcium and sodium ions [3]. It does not couple to G proteins, but directly mediates ion flow upon activation by **glutamate** and **glycine**. Ligand-gated ion channels open a central transmembrane ion channel when a neurotransmitter binds to sites on its extracellular domain [3].*Steroid*- **Steroid hormones** primarily act on **intracellular receptors** that, once activated, translocate to the nucleus to regulate gene expression. They are not cell surface receptors and do not utilize G protein signaling.*Insulin receptors*- **Insulin receptors** are **receptor tyrosine kinases** that, upon binding insulin, undergo autophosphorylation and activate intracellular signaling pathways. They signal through a cascade of protein phosphorylations, not through G proteins.

Q: Which is true for glucuronidation:

Phase II reaction. ***Phase II reaction***- **Glucuronidation** is a major **Phase II** metabolic pathway that conjugates a glucuronic acid molecule to a **lipophilic substance** [1]- This process significantly increases the **water solubility** of the substance, facilitating its excretion from the body [1, 2]- Catalyzed by **UDP-glucuronosyltransferases (UGTs)**, a family of conjugation enzymes [1]*Done by CYP enzyme*- **CYP (cytochrome P450)** enzymes are primarily involved in **Phase I** metabolic reactions, which typically functionalize compounds through oxidation, reduction, or hydrolysis [1]- Glucuronidation is catalyzed by **UDP-glucuronosyltransferases (UGTs)**, not CYP enzymes [1]*Phase I reaction*- **Phase I reactions** (e.g., oxidation, reduction, hydrolysis) introduce or expose polar functional groups on xenobiotics [1]- Glucuronidation is a **conjugation reaction**, characteristic of **Phase II metabolism**, not Phase I [1]*Water solubility is decreased*- Glucuronidation involves the attachment of a **hydrophilic glucuronic acid** molecule to the substrate [1]- This conjugation significantly **increases the water solubility** of the metabolite, which is essential for its efficient urinary or biliary excretion [1, 2]- The addition of the polar glucuronic acid group makes lipophilic compounds more water-soluble [1]

Q: After IV drug administration, elimination of a drug depends on:

Clearance. ***Clearance*** - **Clearance (CL)** is the primary and direct determinant of drug elimination after IV administration. - It represents the **volume of plasma cleared of drug per unit time** (e.g., mL/min or L/hr). - The **rate of elimination** is directly calculated as: Rate = CL × Plasma concentration - Clearance integrates the efficiency of all eliminating organs (liver, kidneys) and is the key parameter determining how fast a drug is removed from the body. - Formula: **CL = Rate of elimination / Plasma concentration** *Lipid solubility* - Lipid solubility affects drug **distribution** and **renal reabsorption** but does not directly determine the rate of elimination. - Highly lipid-soluble drugs may be reabsorbed in renal tubules, but the elimination rate is still governed by clearance. - Lipid solubility is more relevant to drug distribution and metabolism pathways than to the rate of elimination itself. *Volume of distribution* - Volume of distribution (Vd) describes how extensively a drug distributes into tissues versus plasma. - While Vd affects the **half-life** (t½ = 0.693 × Vd/CL), it does NOT directly determine the elimination rate. - A large Vd means more drug in tissues, which affects how long elimination takes, but the actual rate of elimination is still determined by clearance. - Vd is a distribution parameter, not an elimination parameter. *All of the options* - This is incorrect because only **clearance** directly determines the rate of drug elimination. - While lipid solubility and volume of distribution can indirectly influence how long a drug remains in the body, they do not determine the elimination rate itself—clearance does.

Q: All of the following are advantages of transdermal drug delivery systems except

They produce high peak plasma concentration of the drug. ***They produce high peak plasma concentration of the drug*** - Transdermal drug delivery generally aims to provide **sustained**, **controlled drug release** over an extended period, leading to relatively **flat plasma concentration profiles**, not high peaks [1]. - High peak concentrations are more characteristic of bolus intravenous injections or immediate-release oral formulations, which can lead to rapid onset but also potentially higher **adverse effects** [1]. *They minimize interindividual variation in the achieved plasma drug concentration* - Transdermal systems often contribute to **consistent drug absorption**, bypassing factors like gastric emptying time, gut motility, and food interactions, which can vary significantly between individuals. - This consistency helps in achieving more **predictable plasma drug levels** compared to oral routes, reducing variability [4]. *They avoid hepatic first pass metabolism of the drug* - Drugs administered transdermally are absorbed directly into the **systemic circulation**, bypassing the **portal venous system** and liver entirely [4]. - This means the drug avoids being metabolized by **hepatic enzymes** before reaching its site of action, increasing its **bioavailability** [4]. *They produce smooth and nonfluctuating plasma concentration of the drug* - Transdermal patches are designed for **continuous drug release** at a controlled rate, maintaining therapeutic levels of the drug in the blood [2], [3]. - This **steady-state drug delivery** helps avoid the "peaks and troughs" seen with intermittent dosing, which can be associated with side effects or suboptimal efficacy [3].

Q: All of these fluids are isotonic except

3% Normal saline. ***3% Normal saline*** - This fluid is **hypertonic**, meaning it has a higher solute concentration (osmolality ~1025 mOsm/L) than normal body fluids (~280-295 mOsm/L). - It is definitively **not isotonic** [1] and is used to correct severe hyponatremia by drawing water from the intracellular to the extracellular space. - This is the **clearest answer** as it is unambiguously non-isotonic. *5% dextrose* - This solution is **isotonic when infused** (~252 mOsm/L, close to plasma osmolality) but becomes **hypotonic physiologically** as the dextrose is rapidly metabolized, leaving free water [1]. - While technically isotonic at administration, it behaves as a hypotonic solution in the body. - Commonly used for dehydration and as a vehicle for medications. *0.9% Normal saline* - Often called **normal saline**, this is an **isotonic** crystalloid solution (~308 mOsm/L), with osmolality similar to blood plasma [1]. - Widely used for volume expansion, rehydration, and as a maintenance fluid in various clinical settings. *Ringer lactate* - This is an **isotonic** crystalloid solution (~273 mOsm/L) containing sodium, chloride, potassium, calcium, and lactate. - It closely mimics the electrolyte composition of plasma and is preferred for fluid resuscitation and in surgical settings due to its balanced composition.

Q: Elimination of alcohol follows

Zero order kinetics. ***Zero order kinetics*** - Alcohol is metabolized at a **constant rate** (approximately 7-10 grams per hour) regardless of its concentration in the body. - This occurs because the metabolic enzymes like **alcohol dehydrogenase (ADH)** become **saturated** at blood alcohol concentrations typically achieved during drinking. - A **fixed amount** of alcohol is eliminated per unit of time, not a fixed percentage. - **Clinical significance**: This explains why you cannot speed up alcohol elimination by drinking coffee or taking cold showers. *Third Order kinetics* - This kinetic order is **not typically observed** for drug elimination in biological systems. - It would imply an extremely complex relationship between concentration and elimination rate that is not seen in clinical pharmacology. *First order kinetics* - Most drugs follow **first-order kinetics**, where a **constant fraction** (percentage) of the drug is eliminated per unit of time. - This occurs when enzyme systems are **not saturated**, which is **not the case** with alcohol at typical intoxicating doses. - At very low blood alcohol concentrations (below enzyme saturation), alcohol may exhibit first-order kinetics. *Second order kinetics* - **Second-order kinetics** means the elimination rate is proportional to the **square of the drug concentration**. - This type of kinetics is **rarely relevant** for drug elimination in pharmacology.

Q: In noncompetitive antagonism, the true statement is:

Vmax decreased; Km value normal. ***Vmax decreased; Km value normal*** - In **noncompetitive antagonism**, the antagonist binds to an **allosteric site** on the enzyme, altering its conformation and reducing its efficacy regardless of substrate concentration. - This results in a **reduced maximum velocity (Vmax)** because the antagonist effectively removes some enzyme molecules from participating in catalysis, but the **affinity (Km)** of the remaining active sites for the substrate is unaffected. *Km value increased; Vmax increased* - An **increased Km value** indicates a **decreased affinity** of the enzyme for its substrate, while an **increased Vmax** implies **enhanced catalytic activity**, which is not characteristic of any type of antagonism. - This pattern would suggest an enzyme that has been modified to bind less effectively but process substrate more rapidly, which is biologically uncommon in antagonism. *No change in Vmax; Km value decrease* - A **decreased Km value** signifies an **increased affinity** of the enzyme for its substrate, meaning it takes less substrate to reach half of the maximum velocity. - No change in Vmax combined with a decreased Km value is characteristic of **reversible competitive inhibition** at high substrate concentrations, not noncompetitive antagonism. *Km value decrease; Vmax decreases* - A **decreased Km value** suggests an **increased affinity**, meaning the enzyme binds more tightly to the substrate. - This combination is not typical for an antagonist; a reduced Vmax without a change in Km is characteristic of noncompetitive antagonism, while a decreased Km would imply improved binding.

Q: A patient presents with nephrotic syndrome and hypoalbuminemia. Protein binding of which drug is not affected?

Morphine. ***Morphine*** - Morphine is a **low protein-bound drug** (<35%), meaning a significant portion circulates freely. - Therefore, even with **reduced albumin levels** in nephrotic syndrome, the free fraction available for action is not significantly altered. *Valproate* - Valproate is **highly protein-bound** (90-95%), primarily to albumin. - In conditions like nephrotic syndrome with **hypoalbuminemia**, a decreased binding capacity leads to a higher free drug fraction and increased pharmacological effect. *Diazepam* - Diazepam is also **highly protein-bound** (98%), mainly to albumin. - Like other highly bound drugs, **hypoalbuminemia** in nephrotic syndrome would increase its free fraction, potentially leading to increased side effects. *Tolbutamide* - Tolbutamide is another drug with **high protein binding** (>90%), predominantly to albumin. - Reduced albumin levels in nephrotic syndrome would result in a **higher free concentration** of tolbutamide, increasing its hypoglycemic effect and risk of adverse reactions.

Q: Which of the following cytochromes is involved in monooxygenase mediated detoxification of drugs?

Cytochrome P450. ***Cyt P 450*** - **Cytochrome P450** enzymes are a superfamily of **monooxygenases** that play a critical role in the metabolism and detoxification of a wide variety of endogenous and exogenous substances, including drugs. - They facilitate phase I reactions (e.g., **oxidation**, reduction, hydrolysis), which typically introduce or expose functional groups to make compounds more polar and easier to excrete. *Cytochrome b5* - **Cytochrome b5** is involved in various metabolic reactions, including **fatty acid desaturation** and cholesterol biosynthesis, and can sometimes interact with P450 systems but is not the primary monooxygenase for drug detoxification. - It also participates in the reduction of methemoglobin and can act as an electron donor, but its role in drug detoxification is secondary and accessory to P450. *Cytochrome c* - **Cytochrome c** is a key component of the **electron transport chain** in mitochondria, primarily involved in cellular respiration and ATP production. - It has a crucial role in **apoptosis** when released into the cytosol, but it is not directly involved in drug monooxygenase detoxification. *NADPH-cytochrome P450 reductase* - **NADPH-cytochrome P450 reductase** is an enzyme that transfers electrons from NADPH to **cytochrome P450 enzymes**, enabling their monooxygenase activity. - While essential for P450 function, it is the **reductase** (electron donor) and not the monooxygenase enzyme itself, which is Cytochrome P450.

Question 1

Which of the following is a G protein coupled receptor?

Accepted Answer

M2 muscarinic receptor

Answer

NMDA receptor

Answer

Insulin receptors

Answer

Steroid receptors

Question 2

Which is true for glucuronidation:

Accepted Answer

Phase II reaction

Answer

Done by CYP enzyme

Answer

Phase I reaction

Answer

Water solubility is decreased

Question 3

After IV drug administration, elimination of a drug depends on:

Accepted Answer

Clearance

Answer

Lipid solubility

Answer

Volume of distribution

Answer

All of the options

Question 4

Which one of the following is true for competitive antagonism?

Accepted Answer

Agonist and competitive antagonist bind to the same receptor

Answer

Agonist cannot displace an antagonist from the receptor

Answer

Antagonism cannot be completely reversed by an increased dose of an agonist

Answer

Maximum response (Emax) is reduced in the presence of a competitive antagonist

Question 5

All of the following are advantages of transdermal drug delivery systems except

Accepted Answer

They produce high peak plasma concentration of the drug

Answer

They minimize interindividual variation in the achieved plasma drug concentration

Answer

They avoid hepatic first pass metabolism of the drug

Answer

They produce smooth and nonfluctuating plasma concentration of the drug

Question 6

All of these fluids are isotonic except

Accepted Answer

3% Normal saline

Answer

5% dextrose

Answer

0.9% Normal saline

Answer

Ringer lactate

Question 7

Elimination of alcohol follows

Accepted Answer

Zero order kinetics

Answer

Third Order kinetics

Answer

First order kinetics

Answer

Second order kinetics

Question 8

In noncompetitive antagonism, the true statement is:

Accepted Answer

Vmax decreased; Km value normal

Answer

Km value increased; Vmax increased

Answer

No change in Vmax; Km value decrease

Answer

Km value decrease; Vmax decreases

Question 9

A patient presents with nephrotic syndrome and hypoalbuminemia. Protein binding of which drug is not affected?

Accepted Answer

Morphine

Answer

Valproate

Answer

Diazepam

Answer

Tolbutamide

Question 10

Which of the following cytochromes is involved in monooxygenase mediated detoxification of drugs?

Accepted Answer

Cytochrome P450

Answer

Cytochrome b5

Answer

Cytochrome c

Answer

NADPH-cytochrome P450 reductase

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?